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Abstract
Background
India is considering the scale-up of the Xpert MTB/RIF assay for detection of tuberculosis
(TB) and rifampicin resistance. We conducted an economic analysis to estimate the costs of
different strategies of Xpert implementation in India.
Methods
Using a decision analytical model, we compared four diagnostic strategies for TB patients:
(i) sputum smear microscopy (SSM) only; (ii) Xpert as a replacement for the rapid diagnostic
test currently used for SSM-positive patients at risk of drug resistance (i.e. line probe assay
(LPA)); (iii) Upfront Xpert testing for patients at risk of drug resistance; and (iv) Xpert as a
replacement for SSM for all patients.
Results
The total costs associated with diagnosis for 100,000 presumptive TB cases were: (i) US$
619,042 for SSM-only; (ii) US$ 575,377 in the LPA replacement scenario; (iii) US$ 720,523
in the SSM replacement scenario; and (iv) US$ 1,639,643 in the Xpert-for-all scenario. Total
cohort costs, including treatment costs, increased by 46% from the SSM-only to the Xpert-
for-all strategy, largely due to the costs associated with second-line treatment of a higher
number of rifampicin-resistant patients due to increased drug-resistant TB (DR-TB) case
detection. The diagnostic costs for an estimated 7.64 million presumptive TB patients would
comprise (i) 19%, (ii) 17%, (iii) 22% and (iv) 50% of the annual TB control budget. Mean total
costs, expressed per DR-TB case initiated on treatment, were lowest in the Xpert-for-all sce-
nario (US$ 11,099).
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Conclusions
The Xpert-for-all strategy would result in the greatest increase of TB and DR-TB case detec-
tion, but would also have the highest associated costs. The strategy of using Xpert only for
patients at risk for DR-TB would be more affordable, but would miss DR-TB cases and the
cost per true DR-TB case detected would be higher compared to the Xpert-for-all strategy.
As such expanded Xpert strategy would require significant increased TB control budget to
ensure that increased case detection is followed by appropriate care.
Introduction
According to the 2015 World Health Organization (WHO) Global TB Report, India has the
highest tuberculosis (TB) burden in the world. In 2015, an estimated 2.8 million people in
India developed active TB, of which approximately 59% were diagnosed [1]. 28,876 patients
received a laboratory-confirmed MDR-TB diagnosis, which is approximately one third of the
estimated total number of MDR-TB cases [1]. Improving the detection of active TB and of
MDR-TB is among the top priorities of the Revised National TB Control Program (RNTCP)
[2], in line with the WHO End TB Strategy to improve patient-centered TB care and
prevention.
The Xpert MTB/RIF assay (hereafter referred to as Xpert) for the diagnosis of TB and
DR-TB offers great promise as a tool for TB control in India. The WHO-endorsed assay has
greater sensitivity for TB detection than sputum smear microscopy (SSM) [3], high accuracy
for the detection of rifampicin resistance [4], and provides a diagnosis of TB and MDR-TB
from a single sample within 2 hours. Furthermore, a previous economic evaluation found
Xpert to be cost-effective as a replacement for SSM in India [5], with the benefit of increased
case detection. A multisite, phased implementation study conducted to collect evidence for the
scale-up of the Xpert assay for TB and MDR-TB diagnosis in India found that the proportion
of bacteriologically-confirmed TB cases identified, out of the presumptive TB cases tested,
increased by 33% (95% CI 16–52%), while the detection of all patients diagnosed with bacterio-
logically-confirmed or clinically-diagnosed pulmonary TB, combined, increased by 11% (95%
CI 3–21%) compared to SSM [6,7].
Although Xpert has been shown to be easy to implement, and is potentially cost-effective
and successful in increasing the detection of TB and MDR-TB in India [6,7], Xpert access and
uptake in India have been hindered by issues related to cartridge cost, procurement and supply
chain management, a lack of engagement of the private sector (the first point of contact with
the healthcare system for about 70% of patients in India), and a major national TB control pro-
gram (NTP) financial deficit [8,9]. A country-wide implementation of Xpert would require a
considerable increase in the NTP budget [10], and the projected, increased costs for TB diag-
nosis and treatment of additional, identified TB and MDR-TB cases through Xpert scale-up
may well exceed the available budget and compete with other cost-effective health interven-
tions [11]. For these reasons, it is critical to explore the benefits and trade-offs of different
strategies to Xpert implementation in order to inform decisions about the scale-up of the
Xpert assay in India. We conducted an economic analysis to determine the per-patient and
overall costs of diagnosing and treating TB and rifampicin-resistant TB given different diag-
nostic scenarios.
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Methods
Overview
We developed a decision analytical model to simulate a cohort of patients who report to public
health facilities in India with symptoms or signs suggestive of TB and require diagnostic testing
for pulmonary TB [7]. We compared four different scenarios that consider different combina-
tions of diagnostic tests and the target population, or sub-population, for each test. True and
false positive (TP/FP) and true and false negative (TN/FN) cases were estimated for all scenar-
ios, assuming that the tests perform with reported sensitivity and specificity (Table 1)
[3,4,12,13]. We estimated the total costs (in 2013 US dollars) of diagnosing and treating TB
and rifampicin-resistant TB for the cohort, as well as average costs per presumptive TB patient
tested, per true TB case and per rifampicin-resistant TB case detected and initiated on treat-
ment. The primary analysis was conducted from the perspective of a public, TB health care
provider. We also estimated the impact of the total costs of each scenario on the national bud-
get for TB control [1].
Population
The simulated population represented adult patients requiring diagnostic testing for TB,
rifampicin-resistant TB or both. In the primary analysis, the cohort characteristics were stipu-
lated as observed in the implementation study [7], except for the prevalence of bacteriologi-
cally-confirmed (culture positive) pulmonary TB, which was adapted to the national average
(15% in new patients and 27% in patients previously treated for TB) in order to make the con-
clusion more attributable to the national program and not just to the areas included in the
implementation study. In the implementation study [7], the proportion of presumptive TB
patients previously treated for TB, out of all patients with presumptive TB was 16.8% (11,922/
70,556) and the prevalence of rifampicin resistance was 5.6% in new and 24.6% in previously
treated TB patients. Two percent of the cohort comprised TB patients requiring drug resis-
tance testing because of treatment failure (DR-TB suspects). HIV-infection was not considered
due to low prevalence of HIV in India. See Supplement S1 File for further details.
Diagnostic scenarios
Scenario 1. Baseline: Sputum smear microscopy (SSM) only. The baseline scenario rep-
resents the recommended practice in India [14], with SSM being the primary diagnostic tool
for screening of all presumptive TB patients followed by line probe assay (LPA) screening of
patients at increased risk for MDR-TB as recommended by RNTCP. Briefly, SSM was per-
formed on two samples from all presumptive TB patients. Patients with1 positive SSM were
considered a TB case and required TB treatment. SSM negative patients were clinically evalu-
ated following the RNTCP algorithm (Fig A of S1 File). For patients with two negative smears,
the recommendation consisted of 10–14 days of antibiotics followed by two repeat SSM exami-
nations if cough persisted. If these SSM results were negative, TB treatment may be initiated
based on a chest x-ray (CXR) suggestive of TB [7]. In the primary analysis we attempted to
closely reflect actual practice, and thus assumed that all patients received an antibiotic trial,
though only a portion of patients received a CXR [4,13]. In a sensitivity analysis, the NTP’s
newly-proposed algorithm that includes a CXR for all SSM negative patients with presumptive
TB (in locations where Xpert is not accessible) was explored.
To diagnose rifampicin resistance, the sputum of SSM positive TB patients at increased risk
for MDR was tested by LPA. In the model, in all scenarios, patients at increased risk for MDR
included TB patients who failed first-line treatment (DR-TB suspects) as well as patients with a
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Table 1. Model parameters.
Parameter Point
estimate
Range for deterministic sensitivity analysis
Low High Source
Prevalence among simulated cohort
Proportion of patients known to have tuberculosis who require drug resistance
testing ("MDR-suspect")
0.0245 0.000 0.0254 Sachdeva et al. 2014 [7]
Proportion of presumptive TB patients previously treated for TB 0.168 0.019 0.3522 Sachdeva et al. 2014 [7]; average and range
observed across sites
Prevalence of true PTB among new presumptive TB patients 0.15 0.08 0.23 Assumption
Prevalence of true PTB among previously treated presumptive TB patients 0.266 0.183 0.3982 Assumption
Prevalence of RIF resistance among new patients 0.022 0.019 0.0260 WHO report 2014 [1]
Prevalence of RIF resistance among previously treated patients and DR-suspects 0.150 0.110 0.1900 WHO report 2014 [1]
Diagnostic test accuracy
Sensitivity of Xpert MTB/RIF for diagnosing TB 0.89 0.85 0.92 Steingart et al. 2014 [4]
Specificity of Xpert MTB/RIF for diagnosing TB 0.99 0.98 0.99 Steingart et al. 2014 [4]
Sensitivity of Xpert MTB/RIF for Rif detection 0.95 0.90 0.97 Steingart et al. 2014 [4]
Specificity of Xpert MTB/RIF for Rif detection 0.98 0.97 0.99 Steingart et al. 2014 [4]
Sensitivity of sputum smear microscopy (ZN) 0.62 0.44 0.79 Steingart et al. 2006 [12]
Specificity of sputum smear microscopy (ZN) 0.98 0.96 1.00 Steingart et al. 2006 [12]
Sensitivity of LPA in detecting rifampicin resistance 0.99 0.96 1.00 Bwanga et al. 2009 [26]
Specificity of LPA in detecting rifampicin resistance 0.99 0.98 1.00 Bwanga et al. 2009 [26]
Sensitivity of clinical diagnosis in case found negative sputum smear microscopy 0.160 0.10 0.22 Vassall 2011[5]
Alternative source for Sensitivity of clinical diagnosis in case found negative
sputum smear microscopy
0.610 Walusimbi 2013 [24]
Specificity of clinical diagnosis in case found negative sputum smear microscopy 0.942 0.93 0.97 Vassall 2011[5]
Alternative source for specificity of clinical diagnosis in case found negative
sputum smear microscopy
0.690 Walusimbi 2013 [23]
Proportion of sputum smear negative patients getting CXR 0.037 0 1 Vassall 2011[5]
Ratio of proportion of Xpert-negative patients who get CXR, compared to
proportion of smear-negative
0.5 0 1 Assumption
Proportion of Xpert positive patients who are smear negative 0.36 0.355 0.368 Sachdeva et al. 2014 [7]
Diagnostic test unit costs (in US$ 2013)
Cost of sputum smear microscopy (per patient tested) 0.83 0.60 1.10 Microcosting study. Rupert et al. 2017 [15]
Cost of Xpert testing, per patient tested 13.17 12.06 14.72 Microcosting study. Rupert et al. 2017 [15]
Cost of liquid culture, per patient tested 13.42 10.51 16.21 Microcosting study. Rupert et al. 2017 [15]
Cost of line probe assay for DST, per patient tested (1) 21.34 19.50 23.07 Microcosting study. Rupert et al. 2017 [15];
adjusted for 2.2% error rate
Cost of antibiotic trial in clinical diagnosis 3.86 3.86 3.86 Vassall 2011[5]
Cost of CXR 4.0 2.98 5.00 WHO planning and budgeting tool [17]
Cost of clinical diagnosis = cost of antibiotic trial in all patients + cost of CXR
multiplied by the proportion of patients getting CXR
Treatment costs
Full first-line regimen (2RH/4EHRZ) $148 $93 $188 S1
Full first-line retreatment regimen $189 $185 $305 S1
Second-line standard regimen, average for 24 months $5,812 $4,204 $7,421 S1; Fitzpatrick 2012 [21]
Number of weeks on first-line treatment until confirmatory results of LPA are
returned in new Xpert RIF positive patients
2.5 Assumption
Loss to follow-up before treatment initiation (3)
Proportion of sputum smear positive patients not starting treatment in the baseline 0.092 0 0.20 Sachdeva et al. 2014 [7]
Proportion of bacteriologically positive TB patients not starting treatment in the
intervention phase
0.099 0 0.20 Sachdeva et al. 2014 [7]
Proportion clinically diagnosed TB patients not starting treatment 0 Assumption
Additional initial default in DR-TB patients 0.10 0 0.2 Sachdeva et al. 2014 [7]
https://doi.org/10.1371/journal.pone.0184270.t001
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history of TB treatment in the past. This was chosen to stay close to the RCNTP guidelines
which define high-risk TB cases as those TB cases with previous history of anti TB treatment,
TB cases on treatment with positive sputum smear result at any follow up smear examination,
diagnosed TB cases with HIV-co-infection and all pulmonary TB cases who are contacts of a
known MDR TB case [9]. Patients with SSM negative (i.e. clinically diagnosed) TB were not
further tested for drug resistance. Patients with a rifampicin-resistant LPA result were eligible
for second-line TB treatment, according to RNTCP guidelines [9]. Patients newly diagnosed
with TB were started the standard first-line, 6-month treatment regimen (Cat I), and those
previously treated were started on a first-line, 8-month re-treatment regimen (Cat II).
Scenario 2. Xpert MTB/RIF as a replacement for LPA testing. This scenario was identi-
cal to the baseline scenario, except that the Xpert assay replaced LPA for DST following SSM,
and thus was only applied to SSM-positive TB patients at increased risk for MDR.
Scenario 3. Upfront Xpert MTB/RIF testing for presumptive TB patients at increased
risk of MDR. In the third scenario, presumptive TB patients at increased risk for MDR-TB
(as defined in scenario 1) received upfront Xpert testing, rather than SSM. New patients were
tested with SSM as in the baseline scenario. Thus, if new patients were diagnosed with pulmo-
nary TB, they were not subjected to drug resistance testing.
Scenario 4. Upfront Xpert MTB/RIF for all presumptive TB patients. In the upfront
Xpert-for-all scenario, all presumptive TB patients were tested up-front by Xpert, instead of
SSM, regardless of previous history of TB. This scenario is in line with WHO recommenda-
tions [5]. If positive for MTB by Xpert testing, the patient was considered a TB case and
required TB treatment. For presumptive TB cases with a negative Xpert result for MTB, we
assumed that with significantly higher detection rates with Xpert, the proportion of patients
subjected to the clinical diagnostic process would be half of those undergoing the clinical
diagnostic process following SSM (the baseline scenario) [7]. In the sensitivity analysis, we
explored the possibility of fewer patients being subjected to clinical diagnosis after a negative
Xpert result.
After a rifampicin-sensitive Xpert result, a first-line treatment regimen was started (Cat I
or II, according to retreatment status). In case of a rifampicin-resistant result for previously
treated TB cases, second-line treatment was indicated without further diagnostic confirmation.
In new cases, a sputum sample for confirmatory DST by LPA was required. Xpert MTB-posi-
tive, SSM-negative patients, assumed to be 36% [7], for which direct LPA cannot be done on
the patient specimen, required a culture followed by an LPA on the isolate. Second-line treat-
ment was started and changed to first-line treatment if MDR was not confirmed by LPA.
Costs of diagnostic testing
An observational micro-costing study (or ‘bottom-up’ approach) was conducted at seven
study sites to determine the cost of each bacteriological test (SSM, Xpert, LPA, culture, DST)
per patient tested. The results are reported elsewhere [15]. The costs of clinical diagnosis were
taken from earlier studies conducted in India [4]. The costs of TB treatment regimens were
obtained by applying country-specific cost estimates, including cost of drugs, as well as tests
and visits required for treatment monitoring [16–24] (Table 1; A detailed example is available
in the Supplement S1 File).
Outcome measures
The outcomes calculated by the model were the number of TB cases detected and initiated on
TB treatment, divided into true positive and false positive cases as determined by phenotypic
methods. Similarly, MDR cases detected and initiated on treatment were divided in true
Scaling-up Xpert for detection of tuberculosis and rifampicin resistance-economic analysis
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positive and false positive cases. For the primary analysis, estimates for primary loss to follow-
up between bacteriological TB diagnosis and treatment initiation were taken from the two
arms of the Xpert implementation study (9.2 and 9.9% in the baseline and Xpert-for-all sce-
nario, respectively). Loss to follow-up for DR-TB cases before treatment initiation was also
estimated to be 10% based on the previous implementation study [7]. To calculate the impact
of the rollout of different scenarios to the whole country on the national budget for TB control,
we assumed 610 presumptive TB patients were tested per 100,000 people per year, as observed
in the implementation study [7]. Assuming a population of 1,252 million and a TB control
budget of 252 million US$ [1], 7,637,200 presumptive TB patients would be tested per year.
Sensitivity analyses
Deterministic sensitivity analyses were conducted to explore how assumptions and variations
in the parameter estimates affected the total costs of different scenarios, including variation in
the epidemiological parameters, assumptions about test accuracy, as well as the costs of diag-
nostic tests and treatment. Additionally, the assumptions about the use and interpretation
(i.e. sensitivity and specificity) of CXR were explored in more detail, as little data is available
regarding the proportion of patients receiving CXR in different diagnostic algorithms, despite
the fact that the availability of CXR results could substantially affect clinicians’ decisions
regarding empiric therapy and affect diagnostic costs. In the primary analysis, all patients with
negative bacteriology (SSM) results were clinically evaluated, though only 4% of these patients
received a CXR as part of their TB clinical assessment. This estimate was based on previous
observations [4, 13], and resulted in low sensitivity and high specificity of the clinical diagnos-
tic algorithm. In a sensitivity analysis, we explored the effect of different clinical diagnostic sce-
narios on cost and case detection in patients negative for MTB by bacteriological tests. We also
explored the effect of increasing the proportion of these patients receiving a CXR to 100%,
which would increase the sensitivity and lower the specificity [10].
Ethics
Ethical approval was not obtained for this study, as only secondary data were used in these
analyses.
Results
Cohort of 100,000 persons
The proportion of true pulmonary TB cases diagnosed and initiated on treatment among pre-
sumptive TB patients was 62% in both the SSM-only and LPA replacement scenarios, 67% in
the SSM replacement scenario, and 81% in the Xpert-for-all scenario (Table 2). The total num-
ber of patients on TB treatment, in a cohort of 100,000 persons, was highest in the Xpert-for-
all scenario (16,076), but the proportion of false-positive TB diagnoses was lowest in this sce-
nario. Detection of true rifampicin-resistant TB cases was highest (73%) in the Xpert-for-all
scenario, compared to SSM-only (48%), Xpert as an LPA replacement (46%) and Xpert as a
SSM replacement (59%).
The diagnostic costs for the diagnosis of TB and rifampicin-resistant TB in a cohort of
100,000 persons (Table 3) were: US$ 619,042 in the SSM-only scenario, US$ 575,377 in the
LPA replacement scenario, US$ 720,523 in the SSM replacement scenario, and US$ 1,639,643
in the Xpert-for-all scenario. In all scenarios, diagnostic costs were a minor proportion (8–
16%) of total cohort costs, of which treatment costs were the largest component. Total cohort
costs increased by 46% in the Xpert-for-all scenario and 19% in the LPA replacement scenario
Scaling-up Xpert for detection of tuberculosis and rifampicin resistance-economic analysis
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compared to SSM-only. This increase is largely due to the increased costs associated with sec-
ond-line treatment of the additional rifampicin-resistant TB patients identified upon up-front
Xpert testing. The incremental total cohort cost per true TB case initiated on treatment, com-
pared to baseline was US$ 1040 for scenario 4, and $ 1614 for scenario 3 (Table 4).
Population of 7.64 million
When applied to the whole country (Table 5), the total costs for diagnosis of TB and rifampicin
resistance (not including treatment) among an estimated 7.64 million presumptive TB patients
were highest for the Xpert-for-all scenario. Total diagnostic costs would comprise 19% of the
annual TB control budget for SSM-only, 17% for the LPA replacement scenario, 22% for the
SSM replacement scenario, and 50% for the Xpert-for-all scenario. The expanded Xpert
deployment and usage across different scenarios, would lead to an increase in the case detec-
tion of TB, more significantly rifampicin resistant TB cases, which would warrant a substantial
increase in budget for initiating the detected cases with appropriate treatment regimen. In the
Xpert-for-all scenario the cost for 1st line treatment would increase minimally compared to
SSM-only. However, cost for 2nd line treatment would increase by 59%, resulting in an overall
expected 22% increase in total treatment costs. Compared to the SSM-only scenario, the
Xpert-for-all scenario is predicted to result in a $253 million increase in total national costs for
TB diagnosis and treatment.
The mean diagnostic costs (for TB and rifampicin-resistant TB combined) per patient more
than doubled for the Xpert-for-all scenario, from US$ 6.2 for SSM-only to US$ 16.4 (Table 6),
Table 2. TB and rifampicin resistant-TB cases detected and initiated on treatment by each of the 4 diagnostic strategies, in a cohort 100,000
persons.
TB case detection DR-TB case detection
True TB cases
detected and
initiated on
treatment (TP)
False TB cases
detected and initiated
on treatment (FP)
Total number on
TB treatment
(TP+FP)
True
DR-TB
cases
detected
and
initiated
on
treatment
(TP)
False DR-TB cases
detected and initiated
on treatment (FP)
% of all persons
with DR-TB
diagnosis
Total number on
DR-TB treatment
(TP+FP)
Diagnostic Strategy* n (%**) n n n (%) n % n
1. SSM Only 10,188 62% 5,365 15,553 620 48% 36 5% 655
2. Xpert MTB/RIF as a
replacement for LPA testing
10,188 62% 5,365 15,553 595 46% 71 11% 665
3. Xpert MTB/RIF as a
replacement for SSM for
patients with previous TB
history
11,016 67% 4,969 15,985 762 59% 99 12% 861
4. Xpert MTB/RIF for all
patients
13,380 81% 2,697 16,076 945 73% 101 10% 1,046
TP = true positive; DR-TB = drug-resistant TB, i.e. rifampicin-resistant; FP = false positive; SSM = sputum smear microscopy
*Scenario 1: Perform SSM. If SSM positive and patient has been previously treated for TB, use LPA. If SSM negative and patient has been previously
treated for TB, perform culture, LPA and/or DST.
Scenario 2: Perform SSM. If SSM positive and patient has been previously treated for TB, use Xpert in place of LPA. If SSM negative and patient has been
previously treated for TB, perform culture, LPA and/or DST.
Scenario 3: Perform SSM only for patients not at DR-TB risk. Perform Xpert MTB/RIF for patient has been previously treated for TB.
Scenario 4: Perform Xpert MTB/RIF for all patients, regardless of DR-TB risk.
**Out of 16,492 true pulmonary TB cases among presumptive TB patients and 1,288 rifampicin resistant cases in the cohort
https://doi.org/10.1371/journal.pone.0184270.t002
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representing a 102% increase in a mean diagnostic cost per true TB case initiated on treatment.
The increase in mean total costs (including treatment) per true TB case initiated on treatment
was about 11% from the baseline scenario to the Xpert-for-all scenario. Mean total costs per
MDR case initiated on treatment were lowest in the Xpert-for-all scenario (US$ 11,099), and
highest in scenario 2, with SSM as primary diagnostic tool and Xpert based DST, instead of
LPA, for high risk TB cases (US$ 12,092).
In Fig 1, the one-way effect of variation in model parameter values and assumptions on
total cohort costs is shown for the top 18 variables (out of all included) in the Xpert-for all sce-
nario. The largest variation in total costs was due to variation in parameters that increased or
decreased the prevalence of TB in the cohort (in line with regional estimates of TB burden in
India), and variation in parameters that affected second-line treatment cost.
Table 3. Total diagnostic costs and treatment costs to test 100,000 patients, for 4 diagnostic strategies (Cost in US$2013).
Total
diagnostic
costs**
% of
Total
cohort
costs
Patients on
TB
treatment
(TP+FP),
any
regimen
Patients on
DR-TB
treatment
(TP+FP)
Costs for
1st line
treatment
Costs for
2nd line
treatment
Total
Treatment
costs
% of
Total
cohort
costs
Total
cohort
costs
Incremental
total cohort
costs compared
to baseline
Diagnostic
Strategy*
US$ 2013 n n US$ 2013 US$ 2013 US$ 2013 US$ 2013 US$ 2013 %
1. Baseline:
SSM. Clinical
diagnosis. If
prev treated,
LPA if SSM+ or
Culture/LPA/
DST if SSM
negative.
619,042 9% 15,553 655 2,747,408 3,807,122 6,554,530 91% 7,173,573
2. Baseline:
SSM. Clinical
diagnosis. If
prev treated, Xp
to diagnose Rif
Res if SSM+
575,377 8% 15,553 665 2,745,435 3,867,745 6,613,180 92% 7,188,556 14,984 0.2%
3. Xpert MTB/
RIF for
presumptive TB
cases with prev
TB history. SSM
for new patients.
720,523 8% 15,985 861 2,782,695 5,006,646 7,789,340 92% 8,509,863 1,336,290 19%
4. Xpert MTB/
RIF for all
patients
1,639,643 16% 16,076 1,046 2,771,662 6,081,091 8,852,753 84% 10,492,396 3,318,823 46%
TP = true positive; DR-TB = drug-resistant TB, i.e. rifampicin-resistant; FP = false positive; SSM = sputum smear microscopy
*Scenario 1: Perform SSM. If SSM positive and patient has been previously treated for TB, use LPA. If SSM negative and patient has been previously
treated for TB, perform culture, LPA and/or DST.
Scenario 2: Perform SSM. If SSM positive and patient has been previously treated for TB, use Xpert in place of LPA. If SSM negative and patient has been
previously treated for TB, perform culture, LPA and/or DST.
Scenario 3: Perform SSM only for patients not at DR-TB risk. Perform Xpert MTB/RIF for patient has been previously treated for TB.
Scenario 4: Perform Xpert MTB/RIF for all patients, regardless of DR-TB risk.
**Total diagnostic costs include costs for all bacteriological TB and resistance tests and for CXR and/or antibiotic trial
https://doi.org/10.1371/journal.pone.0184270.t003
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Use and interpretation of chest x-rays (CXRs)
If all presumptive TB patients with negative bacteriological tests (SSM or Xpert) received CXR,
the need for TB treatment, both for a true positive and false positive TB diagnosis, would
increase in all scenarios (Table A of S1 File). Total cohort costs would increase by approxi-
mately half in all scenarios, largely due to increased cost for first-line treatment. If CXR would
be applied after negative SSM, but not after a negative Xpert result, TB case detection of true
positive TB cases would be approximately the same in all scenarios. Diagnostic cost would still
be highest in the Xpert-for-all scenario, but total cohort costs would be lowest in this scenario,
as false positive cases would not be initiated on treatment. DR-TB case detection and associ-
ated costs of second-line treatment remained unchanged.
Table 4. Incremental cohort and diagnostic costs per true TB case detected and treated, for 4 diagnostic strategies (Cost in US$2013).
Total
cohort
costs
Total cohort
diagnostic
costs**
Total
cohort
treatment
costs
True TB
cases
detected
and initiated
on
treatment
(TP)
Incremental
True TB cases
compared to
baseline
Incremental
total cohort
costs
compared to
baseline
Incremental total
diagnostic cost (US
$2013) per
incremental true TB
case detected and
initiated on
treatment.
Compared to:
Incremental total
cohort cost (US
$2013) per
incremental True
TB cases detected
and initiated on
treatment.
Compared to:
Diagnostic
Strategy*
US$ 2013 US$ 2013 US$ 2013 n n US$ 2013 Baseline Strategy
3†
Baseline Strategy
3†
1. Baseline:
SSM. Clinical
diagnosis. If
prev treated,
LPA if SSM+ or
Culture/LPA/
DST if SSM
negative.
7,173,573 619,042 6,554,530 10,188
2. Baseline:
SSM. Clinical
diagnosis. If
prev treated, Xp
to diagnose Rif
Res if SSM+
7,188,556 575,377 6,613,180 10,188 - 14,984 n.a. n.a.
3. Xpert MTB/
RIF for
presumptive TB
cases with prev
TB history. SSM
for new
patients.
8,509,863 720,523 7,789,340 11,016 828 1,336,290 123 1614
4. Xpert MTB/
RIF for all
patients
10,492,396 1,639,643 8,852,753 13,380 3,192 3,318,823 320 389 1040 839
TP = true positive; DR-TB = drug-resistant TB, i.e. rifampicin-resistant; SSM = sputum smear microscopy
*Scenario 1: Perform SSM. If SSM positive and patient has been previously treated for TB, use LPA. If SSM negative and patient has been previously
treated for TB, perform culture, LPA and/or DST.
Scenario 2: Perform SSM. If SSM positive and patient has been previously treated for TB, use Xpert in place of LPA. If SSM negative and patient has been
previously treated for TB, perform culture, LPA and/or DST.
Scenario 3: Perform SSM only for patients not at DR-TB risk. Perform Xpert MTB/RIF for patient has been previously treated for TB.
Scenario 4: Perform Xpert MTB/RIF for all patients, regardless of DR-TB risk.
**Total diagnostic costs include costs for all bacteriological TB and resistance tests and for CXR and/or antibiotic trial
† Strategy 3 being the next most effective option
https://doi.org/10.1371/journal.pone.0184270.t004
Scaling-up Xpert for detection of tuberculosis and rifampicin resistance-economic analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0184270 September 7, 2017 9 / 14
Discussion
The WHO calls for the early diagnosis of TB, including universal DST and systematic screen-
ing of high-risk groups, as a critical component of the End TB Strategy. The RNTCP, seeking
to control a growing TB epidemic while operating with a restricted budget, will need informa-
tion regarding the associated costs and benefits to various diagnostic strategies in India to bet-
ter inform Xpert scale-up and uptake and ultimately make progress towards the WHO End TB
goals. This study found the upfront Xpert-for-all strategy to be associated with the greatest
increase in TB and DR-TB case detection, and though it would have the highest associated
total costs, the cost per true DR-TB case detected would be lower compared to the use of Xpert
for DR-TB risk groups only.
The detection of true positive TB and DR-TB cases being highest for the upfront Xpert-for-
all scenario is in line with previous findings [6, 7]. The Xpert for all strategy would increase the
costs for diagnosis and treatment combined by approximately 46%, of which three quarters
would be for increased treatment costs, especially for second-line treatment of additionally
identified patients with DR-TB. Algorithms using Xpert only for patients at risk for MDR-TB
would be more affordable, but less effective in increasing case detection. Also, the mean total
cost per true DR-TB case detected and initiated on treatment would be lower with upfront
Xpert-for-all compared to Xpert for DR-TB risk groups, only, primarily due to the Xpert-for-
all identifying proportionally more DS-TB cases, which are cheaper to treat. The Xpert-for-
all scenario was also the most robust to uncertainty in assumptions about the usage and perfor-
mance of CXR in TB diagnosis. However, an expanded usage of Xpert across different
Table 5. Total diagnostic costs and treatment costs under the TB control program for 4 diagnostic strategies.
Number of
patients
tested
Total
diagnostic
costs
Diagnostic
costs as % of
the budget**
Total number
on TB
treatment: TP
+FP
1st line
treatment
2nd line
treatment
Total number
on DR-TB
treatment: TP
+FP
Total
treatment
costs
Total
costs
Diagnostic
Strategy*
n [millions/
year]
Million US$
2013
(%) n [millions/
year]
Million US
$ 2013
Million US
$ 2013
n [millions/
year]
Million US$
2013
Million
US$
2013
1. SSM Only 7.64 $47.3 19% 1.19 $210 $291 0.050 $453 $548
2. Xpert MTB/RIF as
a replacement for
LPA testing
7.64 $43.9 17% 1.19 $210 $295 0.051 $461 $549
3. Xpert MTB/RIF as
a replacement for
SSM for patients
with previous TB
history
7.64 $55.0 22% 1.22 $213 $382 0.066 $540 $650
4. Xpert MTB/RIF for
all patients
7.64 $125.2 50% 1.23 $212 $464 0.080 $552 $801
All costs are in millions, US$ 2013
TP = true positive; DR-TB = drug-resistant TB, i.e. rifampicin-resistant; FP = false positive; SSM = sputum smear microscopy
*Scenario 1: Perform SSM. If SSM positive and patient has been previously treated for TB, use LPA. If SSM negative and patient has been previously
treated for TB, perform culture, LPA and/or DST.
Scenario 2: Perform SSM. If SSM positive and patient has been previously treated for TB, use Xpert in place of LPA. If SSM negative and patient has been
previously treated for TB, perform culture, LPA and/or DST.
Scenario 3: Perform SSM only for patients not at DR-TB risk. Perform Xpert MTB/RIF for patient has been previously treated for TB.
Scenario 4: Perform Xpert MTB/RIF for all patients, regardless of DR-TB risk.
**The budget of the TB control program reported in the WHO 2014 report. (US$ 252 Million)
https://doi.org/10.1371/journal.pone.0184270.t005
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strategies would require significant increased TB control budget to ensure that increased case
detection is followed by appropriate care.
This study modeled the expected cost associated with roll-out of different Xpert scenarios
to allow for the consideration of different diagnostic strategies for a set sample size given bud-
get limitations. An earlier study demonstrated Xpert MTB/RIF to be a highly cost-effective as a
replacement of SSM in India [4]. This was supported by the even lower average diagnostic
costs per patient detected (and initiated on treatment) seen in this modeling study, which is
largely explained by a lower per-patient test cost of the Xpert assay [15], and a higher preva-
lence of TB and drug-resistance TB in the current study under programmatic conditions. Our
model predicted a 31% increase in detection of bacteriologically-confirmed pulmonary TB for
the Xpert-for-all scenario, which was consistent with the Indian Xpert implementation study
[7].
This study had a number of limitations. First, the analysis applied to patients in the public
sector only. Diagnostics and treatment in the private sector were not included. Moreover, we
assumed that patients made one TB diagnostic effort only, and so test-costs or cases detected
at additional diagnostic visits were not considered [25]. Additionally, HIV-infected patients
were not modeled as a separate group in this study. The HIV prevalence in India is low so the
impact of this assumption on the overall result was expected to be small. Presumptive TB
patients at increased risk of MDR were approximated by patients with a history of previous
TB, comprising 17% of the cohort. Other patients at risk for DR-TB, such as MDR-contacts,
were also not modeled as a separate group, as their number was expected to be small. Addi-
tionally, it should be noted that varying the assumptions about the prevalence of drug resis-
tance in general showed a large effect on the expected total cohort costs, implying that the
Table 6. Mean costs per patient for 4 diagnostic strategies.
Mean diagnostic costǂ Mean treatment costǂ Mean total costǂ
Diagnostic Strategy* per
patient
tested
per TP TB case
initiated on
treatment**
per TP MDR
case
detected
per TP TB
case
detected
per TP MDR
case
detected
per
patient
tested
per TP TB
case
detected
per TP MDR
case
detected
1. SSM Only $6.2 $60.8 $999 $643 $10,579 $71.7 $704.1 $11,578
2. Xpert MTB/RIF as a
replacement for LPA testing
$5.8 $56.5 $968 $649 $11,124 $71.9 $705.6 $12,092
3. Xpert MTB/RIF as a
replacement for SSM for
patients with previous TB
history
$7.2 $65.4 $945 $707 $10,218 $85.1 $772.5 $11,163
4. Xpert MTB/RIF for all
patients
$16.4 $122.5 $1,734 $662 $9,364 $104.9 $784.2 $11,099
TP = true positive; DR-TB = drug-resistant TB, i.e. rifampicin-resistant; FP = false positive; SSM = sputum smear microscopy
ǂAll costs in US$ 2013
*Scenario 1: Perform SSM. If SSM positive and patient has been previously treated for TB, use LPA. If SSM negative and patient has been previously
treated for TB, perform culture, LPA and/or DST.
Scenario 2: Perform SSM. If SSM positive and patient has been previously treated for TB, use Xpert in place of LPA. If SSM negative and patient has been
previously treated for TB, perform culture, LPA and/or DST.
Scenario 3: Perform SSM only for patients not at DR-TB risk. Perform Xpert MTB/RIF for patient has been previously treated for TB.
Scenario 4: Perform Xpert MTB/RIF for all patients, regardless of DR-TB risk.
**All diagnostic costs combined, for TB and DR-TB (16,492 true pulmonary TB cases among presumptive TB patients and 1,288 rifampicin resistant cases
in the cohort).
https://doi.org/10.1371/journal.pone.0184270.t006
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estimation of costs for certain regions may vary considerably along with regional variations in
the distribution of drug resistance [6].
This study took the perspective of a TB service-provider. Therefore, costs encountered by
the patients themselves, whether direct or indirect, were not considered in this analysis. Nota-
bly, patient pathways to TB diagnosis are complex and often include providers other than, or
in addition to, those encountered in the public sector [25]. However, a diagnostic test such as
Xpert, with higher sensitivity, would be expected to reduce the number of TB patient visits,
especially given a reduction in the number of additional visits for CXR and/or repeat testing
after negative test results were obtained. Practices related to clinical diagnosis and the use of
CXR, as well as variation in SSM sensitivity (reflecting smear method and quality variations)
may also have a substantial effect on costs, including treatment costs, even if the patients them-
selves paid the cost of CXR.
The uptake of rapid TB and DR-TB diagnostics such as Xpert MTB/RIF has become an
RNTCP implementation priority as India works to control a growing TB epidemic. Economic
modeling of the TB epidemic in India and different diagnostic strategies found the Xpert-for-
Fig 1. Tornado diagram showing the effect of variation in each parameter value on total costs (US$ per patient tested) for the
Xpert for all scenario.
https://doi.org/10.1371/journal.pone.0184270.g001
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all strategy to be the most costly, though it was the most effective in improving case detection
and had the lowest mean total costs per DR-TB case initiated on treatment. Given current bud-
get limitations, the RNTCP will have to consider these findings in the context of other TB con-
trol activities to determine the best approach to Xpert scale-up for TB and DR-TB control in
India.
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